Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.35 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1405732 | 0.97 | DNM1 (0.55) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL4395109 | 0.97 | DNM1 (0.55) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL15899616 | 0.97 | DNM1 (0.55) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL4391178 | 0.97 | DNM1 (0.55) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL7646024 | 0.97 | DNM1 (0.55) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL11071352 | 0.97 | DNM1 (0.55) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL11125895 | 0.94 | DNM1 (0.52) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL11124727 | 0.94 | DNM1 (0.46) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL7283453 | 0.91 | DNM1 (0.50) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL78616 | 0.90 | TSHR (0.40) | DNM1TSHRTHRBCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725589-B2 | Method of preparing acrylic polymers and products produced thereby | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2017-08-08 | — | — | US | claimed |
| US-20140336343-A1 | Method Of Preparing Acrylic Polymers And Products Produced Thereby | LUBRIZOL ADVANCED MATERIALS, INC. | 2014-11-13 | — | — | US | claimed |
| EP-2794672-A1 | METHOD OF PREPARING ACRYLIC POLYMERS AND PRODUCTS PRODUCED THEREBY | Lubrizol Advanced Materials, Inc. (US) | 2014-10-29 | — | — | EP | claimed |
| WO-2013096206-A1 | METHOD OF PREPARING ACRYLIC POLYMERS AND PRODUCTS PRODUCED THEREBY | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2013-06-27 | — | — | WO | claimed |
| EP-0222839-A4 | ANTIMALARIAL COMPOUNDS. | UNIV AUSTRALIAN (AU) | 1988-11-09 | — | — | EP | claimed |
| EP-0222839-A1 | ANTIMALARIAL COMPOUNDS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1987-05-27 | — | — | EP | claimed |
| WO-1986006718-A1 | ANTIMALARIAL COMPOUNDS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1986-11-20 | — | — | WO | claimed |
| US-11975002-B2 | Preparation and composition for treatment of malignant tumors | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-05-07 | — | — | US | disclosed |
| US-11883404-B2 | Preparation and composition for treatment of malignant tumors | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2024-01-30 | — | — | US | disclosed |
| EP-3864002-B1 | ADDITION-FRAGMENTATION AGENT WITH PENDENT AMINE GROUPS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11690843-B2 | — | — | 2023-07-04 | — | — | US | disclosed |
| US-20220033345-A1 | ADDITION-FRAGMENTATION AGENT WITH PENDENT AMINE GROUPS | 3M INNOVATIVE PROPERTIES COMPANY | 2022-02-03 | — | — | US | disclosed |
| EP-3864002-A1 | ADDITION-FRAGMENTATION AGENT WITH PENDENT AMINE GROUPS | 3M Innovative Properties Company (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-0222839-A4 | ANTIMALARIAL COMPOUNDS. | UNIV AUSTRALIAN (AU) | 1988-11-09 | — | — | EP | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
| EP-0222839-A1 | ANTIMALARIAL COMPOUNDS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1987-05-27 | — | — | EP | disclosed |
| EP-0215435-A1 | 2-Oxa-isocephem compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-03-25 | — | — | EP | disclosed |
| WO-1986006718-A1 | ANTIMALARIAL COMPOUNDS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1986-11-20 | — | — | WO | disclosed |
| EP-0052016-B1 | CARBOSTYRIL COMPOUNDS, COMPOSITIONS CONTAINING SAME AND PROCESSES FOR PREPARING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-09-05 | — | — | EP | disclosed |
| US-4414390-A | CARDIOTONIC AGENTS | OTSUKA, PHARMACEUTICAL CO., LTD. (JP) | 1983-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690843-B2 | — | FGFR3, FGFR1, FGFR4 | DNM1 1637/4885TSHR 3877/4885THRB 2400/4885 |
| US-11975002-B2 | Preparation and composition for treatment of malignant tumors | FGFR3, FGFR1, FGFR4 | DNM1 996/4885TSHR 3712/4885THRB 2406/4885 |
| US-11883404-B2 | Preparation and composition for treatment of malignant tumors | FGFR3, FGFR1, FGFR4 | DNM1 996/4885TSHR 3712/4885THRB 2406/4885 |
| US-20220033345-A1 | ADDITION-FRAGMENTATION AGENT WITH PENDENT AMINE GROUPS | PARP1, ETFA, PARP2 | DNM1 414/4885TSHR 3927/4885THRB 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.